Claims
- 1. A compound of formula Iaa (or a pharmaceutically acceptable salt thereof): whereinA2 is an aromatic or heteroaromatic divalent radical selected from para-phenylene, a 6-membered ring heteroaromatic divalent radical containing 1 or 2 ring nitrogens and a 5-membered ring heteroaromatic divalent radical containing one oxygen or sulfur ring atom and 0, 1 or 2 ring nitrogens in which heteroaromatic divalent radical the valences are in the 1,4- or 2,5- or 3,6-relationship; A3 is an aromatic or heteroaromatic divalent radical selected from para-phenylene, a 6-membered ring heteroaromatic divalent radical containing 1 or 2 ring nitrogens and a 5-membered ring heteroaromatic divalent radical containing one oxygen or sulfur ring atom and 0, 1 or 2 ring nitrogens in which heteroaromatic divalent radical the valences are in the 1,4- or 2,5- or 3,6-relationship and which divalent radical may bear a (1-3C)alkyl or halo substituent; R1 denotes 0, 1 or 2 substituents on the benz-ring independently selected from halo, methyl, ethyl, hydroxy, methoxy, carbamoyl, aminomethyl and hydroxymethyl; A′ is S; X1′ is O or S; X2′ is O or S; X3′ is a direct bond, methylene, imino, or S; q is 0, 1 or 2; and r is 0 or 1; provided that q and r are not both zero, and provided that when q is 1 and r is 0, then X3′ is a direct bond; each R3 is hydrogen or the two R3 groups together form a divalent radical —(CH2)s— in which s is 3 or 4; Rc and Rd are independently (1-3C)alkyl or the group NRcRd is pyrrolidino, piperidino, morpholino, hexamethyleneimino or 1-imidazolyl; R4 is methyl or Si(t-Bu)(Me)2.
- 2. A compound of formula Ia′: whereinD is CH or N; E is CH, CRe or N in which Re is (1-3C)alkyl or halo; R5 is hydrogen, halo, methyl, hydroxy or methoxy; R6 is hydrogen, hydroxy or methoxy; A′ is S; X1′ is O or S; X2a′ is O; x3a′ is methylene, imino or S; and each R3 is hydrogen or the two R3 groups together form a divalent radical —(CH2)s— in which s is 3 or 4; and Rc and Rd are independently (1-3C)alkyl or the group NRcRd is pyrrolidino, piperidino, morpholino, hexamethyleneimino or 1-imidazolyl; and R4 is methyl or Si(t-Bu)(Me)2.
Parent Case Info
This application is a continuation of application U.S. Ser. No. 08/846,647 filed Apr. 30, 1997, now U.S. Pat. No. 6,025,382 which is a continuation-in-part of U.S. Ser. No. 08/836,680, filed Apr. 30, 1997 now abandoned, which is continuation of application PCT/US96/17995, filed Oct. 31, 1996, which international application claims priority from U.S. provisional application No. 60/007,120, filed Oct. 31, 1995, and U.S. provisional application No. 60/028,252, filed Oct. 9, 1996.
This application is a continuation-in-part of copending U.S. national application serial number (unknown), the national stage application of international application PCT/US96/17995, filed Oct. 30, 1996, which international application claims priority from U.S. provisional application No. 60/007,120, filed Oct. 31, 1995, and U.S. provisional application No.60/028,252, filed Oct. 9, 1996.
US Referenced Citations (14)
Foreign Referenced Citations (2)
Number |
Date |
Country |
0838 464 A1 |
Apr 1998 |
EP |
WO 9510513 |
Apr 1995 |
WO |
Non-Patent Literature Citations (5)
Entry |
Delgado JN and Remers WA. Wilson and Gisvold's Textbook of Organic medicinal and Pharmaceutical Chemistry. Ninth Edition. J.B. Lippincott Company. Philadelphia. pp. 30-31, 1991.* |
Greene TW and Wuts PGM. Protective Groups in Organic Synthesis. Second Edition. John Wiley & Sons, Inc. New York. pp. 12, 77-79, 1991.* |
U.S. application No. 08/956,802, Marron et al., filed Oct. 23, 1997. |
Jones, C., et al., “Synthesis and Antiestrogenic Activity of [3,4-Dihydro-2-(4-methoxyphenyl) -1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methanone, Methanesulfonic Acid Salt”, J. Med. Chem., 22(8), 962-966. |
Jones, C., et al., “Antiestrogens. 2. Structure-Activity Studies in a Series of 3-Aroyl-2-arylbenzo[b]thiophene Derivatives Leading to [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride (LY156758), a Remarkably Effective Estrogen Antagonist with Only Minimal Intrinsic Estrogencity,” J. Med. Chem., 27(8), 1057-1066. |
Provisional Applications (2)
|
Number |
Date |
Country |
|
60/028252 |
Oct 1996 |
US |
|
60/007120 |
Oct 1995 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
08/846647 |
Apr 1997 |
US |
Child |
09/369416 |
|
US |
Parent |
PCT/US96/17995 |
Oct 1996 |
US |
Child |
08/836680 |
|
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08/836680 |
Apr 1997 |
US |
Child |
08/846647 |
|
US |